Comparative Pharmacology
Head-to-head clinical analysis: INTRALIPID 10 versus LIQREV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INTRALIPID 10 versus LIQREV.
INTRALIPID 10% vs LIQREV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Intralipid 10% is a fat emulsion that provides essential fatty acids (linoleic and linolenic acids) and a source of energy. It acts as a carrier for fat-soluble vitamins and prevents essential fatty acid deficiency. The mechanism involves direct utilization of triglycerides for energy after hydrolysis by lipoprotein lipase.
Liqrev (sildenafil) is a phosphodiesterase-5 (PDE5) inhibitor. It enhances the effect of nitric oxide by inhibiting PDE5, which degrades cGMP in the corpus cavernosum, leading to increased cGMP levels and smooth muscle relaxation, thereby facilitating penile erection.
Intravenous infusion. Adult: 500 mL of 10% emulsion (50 g fat) over 4-6 hours, up to 2.5 g fat/kg/day. Maximum infusion rate: 0.1 g fat/kg/hour.
LIQREV (ivermectin) 200 mcg/kg orally once, taken on an empty stomach with water.
None Documented
None Documented
The terminal elimination half-life of Intralipid triglycerides is approximately 30-60 minutes in adults with normal lipid metabolism. In neonates and patients with impaired clearance, half-life may be prolonged to 2-4 hours. Clinical context: half-life increases with infusion rate; at steady state, clearance is rapid due to extrahepatic lipolysis.
Terminal elimination half-life is 12–15 hours in healthy adults; prolonged to 24–30 hours in moderate renal impairment (CrCl <50 mL/min).
Intralipid 10% (IV fat emulsion) is metabolized like endogenous chylomicrons; elimination is not via renal or biliary routes. Triglycerides are hydrolyzed by lipoprotein lipase, and the resulting free fatty acids are taken up by tissues. Less than 0.5% is excreted unchanged in urine. Biliary excretion of metabolites is negligible.
Primarily renal (70% as unchanged drug, 15% as glucuronide conjugate); 10% biliary/fecal.
Category C
Category C
Intravenous Fat Emulsion
Intravenous Fat Emulsion